Xiaobin Wu Sells 39,936 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock

Key Points

• Xiaobin Wu, COO of BeOne Medicines Ltd., sold a total of 39,936 shares on August 14th for over $12 million, following a similar transaction just a day earlier involving 49,858 shares.
• BeOne Medicines recently reported an EPS of $0.84 for the last quarter, exceeding expectations of $0.48, and had revenue of $1.32 billion.
• The stock price of BeOne Medicines fluctuated, reaching $321.36 recently, with analysts recently upgrading their price targets to between $330.00 and $365.00 per share.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 39,936 shares of the stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $305.06, for a total transaction of $12,182,876.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, August 13th, Xiaobin Wu sold 49,858 shares of BeOne Medicines stock. The stock was sold at an average price of $304.16, for a total transaction of $15,164,809.28.
• On Monday, June 23rd, Xiaobin Wu sold 1,363 shares of BeOne Medicines stock. The stock was sold at an average price of $260.00, for a total transaction of $354,380.00.
• On Tuesday, June 17th, Xiaobin Wu sold 630 shares of BeOne Medicines stock. The shares were sold at an average price of $250.87, for a total transaction of $158,048.10.
• On Monday, June 16th, Xiaobin Wu sold 1,543 shares of BeOne Medicines stock. The stock was sold at an average price of $265.52, for a total transaction of $409,697.36.
• On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The stock was sold at an average price of $253.15, for a total value of $489,592.10.

BeOne Medicines Price Performance

NASDAQ ONC traded up $11.67 during trading on Friday, hitting $321.36. The company's stock had a trading volume of 448,792 shares, compared to its average volume of 437,341. BeOne Medicines Ltd. - Sponsored ADR has a fifty-two week low of $170.99 and a fifty-two week high of $321.69. The company has a market capitalization of $35.22 billion, a P/E ratio of -185.76 and a beta of 0.27. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The firm's 50 day moving average is $274.62.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.36. The firm had revenue of $1.32 billion during the quarter, compared to analysts' expectations of $1.24 billion. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%. Analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Guggenheim raised their price target on BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Morgan Stanley raised their price objective on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research report on Friday, June 27th. Wall Street Zen raised BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Royal Bank Of Canada raised their price objective on BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Finally, TD Securities reissued a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a research report on Thursday, April 24th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $330.89.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently made changes to their positions in the business. Primecap Management Co. CA purchased a new stake in shares of BeOne Medicines during the second quarter worth approximately $1,231,720,000. Temasek Holdings Private Ltd acquired a new position in BeOne Medicines during the second quarter worth $244,603,000. Marshall Wace LLP acquired a new position in BeOne Medicines during the second quarter worth $113,190,000. Baird Financial Group Inc. acquired a new position in BeOne Medicines during the second quarter worth $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in BeOne Medicines during the second quarter worth $73,347,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.